Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Northwest Biotherapeutics, Inc. (NWBO) had Return on Equity of 24.69% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$0.20M |
|
$-27.18M |
|
-- |
|
$0.20M |
|
$14.52M |
|
$-14.32M |
|
$-12.51M |
|
$-26.83M |
|
$-26.83M |
|
$-26.83M |
|
$-26.83M |
|
$-26.83M |
|
$-26.83M |
|
$-14.32M |
|
$-13.46M |
|
1.49B |
|
1.49B |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$7.20M |
|
$16.87M |
|
$23.41M |
|
$30.61M |
|
$87.91M |
|
$24.62M |
|
$37.95M |
|
$125.86M |
|
$-108.65M |
|
$-97.17M |
|
$-95.25M |
|
1.52B |
|
| Cash Flow Statement Financials | |
$-30.00M |
|
$-0.91M |
|
$35.74M |
|
$2.17M |
|
$4.56M |
|
$2.38M |
|
$1.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.08 |
|
-- |
|
-- |
|
-0.35 |
|
-0.68 |
|
100.00% |
|
-7160.00% |
|
-7160.00% |
|
-- |
|
-13414.50% |
|
-13591.00% |
|
$-30.60M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
24.69% |
27.61% |
|
-87.65% |
|
37.98% |
|
$-0.06 |
|
$-0.02 |
|
$-0.02 |
|